Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ceras-peg, Certolizumab Pegol Biosimilar (Paras Biopharmaceuticals), PA-2020 + [2] |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Preclinical | FI | - |